` LFWD (Rewalk Robotics Ltd) vs S&P 500 Comparison - Alpha Spread

LFWD
vs
S&P 500

Over the past 12 months, LFWD has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's +14% growth.

Stocks Performance
LFWD vs S&P 500

Loading
LFWD
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LFWD vs S&P 500

Loading
LFWD
S&P 500
Difference
www.alphaspread.com

Performance By Year
LFWD vs S&P 500

Loading
LFWD
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Rewalk Robotics Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Rewalk Robotics Ltd
Glance View

Market Cap
10.4m USD
Industry
Health Care

ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.

LFWD Intrinsic Value
3.01 USD
Undervaluation 81%
Intrinsic Value
Price
Back to Top